Regend Therapeutics

CDMO focused on manufacturing of cell & gene therapy services

placeSuzhou, Jiangsu, China calendar_todayFounded 2015 language regend.cn

Innovation

11 patent families — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 151 times.

YearFilings
20171
20204
20213
20225
20232

Investor mix

13 investors on record; lead investors include Shenzhen Capital Group.

Investor typeCountShare
Venture capital431%
Private equity18%
Bank & private debt18%
Other / undisclosed754%
Coming soon